Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus
Observational study · 2007
- What was studied
- Type-1 diabetes patients receiving adjunctive care
- Main finding
- Adjunctive Vilon in type 1 diabetes was associated with immune and coagulation-marker changes, including antithrombin III, protein C and fibrinolysis. No autoimmune disease-modifying effect is established.
Reported findings and study design
Population or model Type-1 diabetes patients receiving adjunctive care
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Immune and coagulation markers | Reported changes during adjunctive Vilon treatment; numerical effect sizes not supplied |
Type 1 diabetes report, not proof of beta-cell preservation, restored tolerance or replacement of insulin. Possible overlap with the 2006 publication prevents pooling.
Source for these results ↗ · Reviewed 2026-11-05
Study limitations and source details
Study limitations
- The abstract leaves enrollment and allocation unclear. Its findings cannot establish an alternative to insulin.
- Full methods, adverse-event reporting and independent replication remain to be appraised.
Source details
Journal publication
Europe PMC indexed citation and abstract checked. Full original paper not reviewed.
Sources checked
Citation
Kuznik BI, Isakova NV, Kliuchereva NN, Maleeva NV, Pinelis IS. Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus Advances in gerontology = Uspekhi gerontologii 20(2):106-115. PMID 18306698